Aortic Aneurysm Market - Global Forecast 2025-2032

The aortic aneurysm market is undergoing a transformation driven by technology integration, process optimization, and evolving clinical practice. Senior decision-makers need targeted, practical intelligence to drive competitive strategies and respond efficiently as new solutions and care models emerge.

Market Snapshot: Aortic Aneurysm Market Size and Growth

The aortic aneurysm market reached USD 4.79 billion in 2024, with forecasts projecting a rise to USD 5.22 billion by 2025 and a compound annual growth rate (CAGR) of 8.97%. By 2032, the market is expected to achieve USD 9.53 billion. This momentum is propelled by the steady transition to minimally invasive endovascular procedures, advances in biomaterials and device engineering, and broader recognition of vascular disease challenges. While the Americas, Europe, Asia-Pacific, and the Middle East & Africa remain at the forefront, market participants pursue broad investment, geographic diversification, and regulatory adaptability to sustain growth and market presence.

Aortic Aneurysm Market: Scope & Segmentation

This in-depth report is tailored for executives shaping aortic aneurysm strategy, investment, and resource planning. It covers critical segmentation domains and highlights areas where procurement, innovation, and patient care intersect, providing decision-useful insight into prevailing and emerging industry trends:

• Treatment Modality: Assessment of both endovascular stent grafting and open surgical repair, focusing on patient suitability and technology differentiation.
• Aneurysm Type: Evaluation of clinical management for abdominal versus thoracic aneurysms, considering anatomical variations and intervention pathways.
• End User: Impact analysis of care settings—including hospitals and ambulatory surgery centers—on device selection and operational workflow.
• Device Type: Review of stent graft and synthetic vascular graft adoption, matched to geography and intended clinical application.
• Indication: Exploration of management approaches for elective and urgent interventions, highlighting the strategic contribution of new technologies.
• Patient Age Group: Comparison of clinical needs for older and younger patients, integrating trends in comorbidities and risk stratification.
• Gender: Analysis of gender-based differences in intervention and therapy optimization for more personalized patient outcomes.
• Geographies: Examination of regional regulatory dynamics and market trends across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with attention to country-specific factors.
• Leading Companies: Profiles of principal manufacturers—including Medtronic plc, W. L. Gore & Associates, Inc., Cook Medical LLC, Endologix, Inc., Terumo Corporation, Lombard Medical Inc., Jotec GmbH, Bolton Medical Limited, Artivion, Inc., and MicroPort Scientific Corporation—outlining their role in advancing technology and shaping procurement dynamics.

Key Takeaways for Senior Decision-Makers

• Minimally invasive endovascular treatments are now foundational to aortic aneurysm care, continually expanding inclusion criteria and encouraging adoption among wider patient populations.
• Although technological advances are significant, open surgical repair remains essential where complex anatomical presentations restrict the use of endovascular devices.
• Advanced imaging technologies—such as ultrasound, CT angiography, MRI, and tools powered by artificial intelligence—enhance diagnostic precision and support personalized treatment strategies.
• Next-generation stent grafts and new biomaterials foster tailored care, enabling improved patient outcomes even in cases with complex comorbidities.
• Hospitals and ambulatory care centers are optimizing workflows and procurement strategies to achieve value-based care objectives and greater supply chain efficiency.
• Collaborative partnerships between device manufacturers and healthcare networks encourage integrated system deployments, aligning innovation with patient monitoring and long-term care initiatives.

Tariff Impact: Navigating Policy Shifts in the United States

Recent tariffs on select aortic aneurysm devices and graft components in the United States have heightened cost pressures, influencing procurement and supply strategies. Manufacturers are adopting local production and revising inventory management, while providers implement risk-sharing contracts to stabilize device access and manage cost variability. These changes are also accelerating the demand for expedited local regulatory approval processes and driving short-term adjustments in pricing and distribution models.

Methodology & Data Sources

This analysis synthesizes data from peer-reviewed publications, regulatory filings, and government healthcare policy. Contributions from clinicians, supply chain leaders, and hospital administrators are combined with procurement and usage data to inform findings and validate industry trends.

Why This Report Matters for Strategic Planning

• Enables executive teams to refine technology selection and purchasing, optimizing partnerships and leadership positioning within the aortic aneurysm market.
• Equips decision-makers to anticipate and adapt to clinical, regulatory, and policy changes impacting supply chain continuity and resource allocation.
• Supports alignment of organizational objectives with demographic shifts, emerging care models, and best-practice technology adoption to ensure sustained market relevance.

Conclusion

This report delivers actionable, data-driven guidance for leaders tackling the complexities of aortic aneurysm management, helping organizations adapt swiftly to technological change and evolving patient demands.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.